Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Nakai K et al.  
Boron Neutron Capture Therapy for Glioblastoma: A Phase-I/II Clinical Trial at JRR-4

European Association of NeuroOncology Magazine 2014; 4 (3): 116-123

PDF    Summary    Figures   

Fig. 1: BNCT Fig. 2a-b: GBM patient Fig. 3: BNCT Fig. 4: BNCT

Keywords: adverse eventboron neutron capture therapyefficacyglioblastomaradiation therapysafety

Boron neutron capture therapy (BNCT) is a cell-selective radiation therapy for the treatment of glioblastoma. We reviewed the experience of our BNCT clinical trial and report the present state in 17 cases. Endpoints of our analysis were the efficacy and safety data of BNCT for newly diagnosed glioblastoma. Adverse events seen in our patients included post-treatment brain oedema, convulsion, and diplopia due to swallowing. For newly diagnosed glioblastoma (GBM), median overall survival (OS) reached 25.7 months, and the 1- and 2-year OS rates were 85.7 % and 45.5 %, respectively. BNCT could prolong OS in selected cases.
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum